CASC3 and glioblastoma: For GBM, BTZ has been shown to reduce levels of MGMT in T98G cells in vitro, which harbour a partially unmethylated MGMT promoter and further shown to induce apoptosis in these cells when administered prior to TMZ12,13 associated with activation of NFκB, MAPK, STAT3 and HIF-1α pathways.